Work Packages
THRIVE is organised in 11 complementary and inter-related Work Packages (WP)
WP2Determinants of liver cancer
It will address an unresolved question in the field, defining key determinants of a) liver cancer development in specific cohorts of patients with metabolic-associated fatty liver disease (MAFLD), which is the leading cause of liver cancer in adults; and b) progression of hepatoblastoma, the primary form of liver cancer in children.
WP3Molecular tumour-host interactions
It will use cutting-edge molecular technologies, such as single-cell sequencing and spatial transcriptomics, to provide insights regarding tumour-host interactions in liver cancer
WP4Intratumoral microbiome
In WP4, we will dissect liver tumours from a completely unique angle, namely exploring the role of the intratumoral microbiome and its implication in tumour-host interactions.
WP5Biomarkers of response to treatment
It will be devoted at identifying biomarkers of response/resistance to immune-based therapies in hepatocellular carcinoma, and of resistance to chemotherapy in paediatric hepatoblastoma patients, considering molecular, immune and microbiome factors.
WP6Artificial-intelligence-based biomarkers of response to treatment
We will specifically develop artificial-intelligence-based tools using high-resolution histological images to further explore prediction of response in hepatocellular carcinoma and hepatoblastoma
WP7New therapies
Knowledge derived from WP2 to WP6 will fuel WP7, devoted to identifying novel therapeutic strategies aimed at overcoming resistance to the current standard-of-care therapies in childhood and adult liver cancer patients
WP8Data integration to UNCAN.eu
The UNCAN.eu initiative aims to achieve the next breakthrough needed to advance the understanding of cancer mechanisms in order to improve cancer prevention, early diagnosis and treatment, providing a basis for saving millions of European citizens’ lives
WP9Project management and coordination
It will be dedicated to the THRIVE project management and coordination
WP10Communication, dissemination and exploitation
It will deal with communication & dissemination of all THRIVE information generated, exploitation and interaction with EU funded activities.
WP11Promoting social impact
It will ensure the social impact and viability of THRIVE beyond the grant period; and promote networking, exchange of knowledge, establishment of best practices and interaction with patients and policymakers.
WP1Tissue and Data Management
It is a transversal work package and will focus on Tissues and Data Management and it is closely connected to WP2, WP3 and WP4 which will be developed in parallel
WP2Determinants of liver cancer
It will address an unresolved question in the field, defining key determinants of a) liver cancer development in specific cohorts of patients with metabolic-associated fatty liver disease (MAFLD), which is the leading cause of liver cancer in adults; and b) progression of hepatoblastoma, the primary form of liver cancer in children.
WP3Molecular tumour-host interactions
It will use cutting-edge molecular technologies, such as single-cell sequencing and spatial transcriptomics, to provide insights regarding tumour-host interactions in liver cancer
WP4Intratumoral microbiome
In WP4, we will dissect liver tumours from a completely unique angle, namely exploring the role of the intratumoral microbiome and its implication in tumour-host interactions.
WP5Biomarkers of response to treatment
It will be devoted at identifying biomarkers of response/resistance to immune-based therapies in hepatocellular carcinoma, and of resistance to chemotherapy in paediatric hepatoblastoma patients, considering molecular, immune and microbiome factors.
WP6Artificial-intelligence-based biomarkers of response to treatment
We will specifically develop artificial-intelligence-based tools using high-resolution histological images to further explore prediction of response in hepatocellular carcinoma and hepatoblastoma
WP7New therapies
Knowledge derived from WP2 to WP6 will fuel WP7, devoted to identifying novel therapeutic strategies aimed at overcoming resistance to the current standard-of-care therapies in childhood and adult liver cancer patients
WP8Data integration to UNCAN.eu
The UNCAN.eu initiative aims to achieve the next breakthrough needed to advance the understanding of cancer mechanisms in order to improve cancer prevention, early diagnosis and treatment, providing a basis for saving millions of European citizens’ lives
WP9Project management and coordination
It will be dedicated to the THRIVE project management and coordination
WP10Communication, dissemination and exploitation
It will deal with communication & dissemination of all THRIVE information generated, exploitation and interaction with EU funded activities.
WP11Promoting social impact
It will ensure the social impact and viability of THRIVE beyond the grant period; and promote networking, exchange of knowledge, establishment of best practices and interaction with patients and policymakers.
WP2Determinants of liver cancer
It will address an unresolved question in the field, defining key determinants of a) liver cancer development in specific cohorts of patients with metabolic-associated fatty liver disease (MAFLD), which is the leading cause of liver cancer in adults; and b) progression of hepatoblastoma, the primary form of liver cancer in children.
WP3Molecular tumour-host interactions
It will use cutting-edge molecular technologies, such as single-cell sequencing and spatial transcriptomics, to provide insights regarding tumour-host interactions in liver cancer
WP4Intratumoral microbiome
In WP4, we will dissect liver tumours from a completely unique angle, namely exploring the role of the intratumoral microbiome and its implication in tumour-host interactions.
WP5Biomarkers of response to treatment
It will be devoted at identifying biomarkers of response/resistance to immune-based therapies in hepatocellular carcinoma, and of resistance to chemotherapy in paediatric hepatoblastoma patients, considering molecular, immune and microbiome factors.
WP6Artificial-intelligence-based biomarkers of response to treatment
We will specifically develop artificial-intelligence-based tools using high-resolution histological images to further explore prediction of response in hepatocellular carcinoma and hepatoblastoma
WP7New therapies
Knowledge derived from WP2 to WP6 will fuel WP7, devoted to identifying novel therapeutic strategies aimed at overcoming resistance to the current standard-of-care therapies in childhood and adult liver cancer patients
WP8Data integration to UNCAN.eu
The UNCAN.eu initiative aims to achieve the next breakthrough needed to advance the understanding of cancer mechanisms in order to improve cancer prevention, early diagnosis and treatment, providing a basis for saving millions of European citizens’ lives
WP9Project management and coordination
It will be dedicated to the THRIVE project management and coordination
WP10Communication, dissemination and exploitation
It will deal with communication & dissemination of all THRIVE information generated, exploitation and interaction with EU funded activities.
WP11Promoting social impact
It will ensure the social impact and viability of THRIVE beyond the grant period; and promote networking, exchange of knowledge, establishment of best practices and interaction with patients and policymakers.
WP1Tissue and Data Management
It is a transversal work package and will focus on Tissues and Data Management and it is closely connected to WP2, WP3 and WP4 which will be developed in parallel
WP2Determinants of liver cancer
It will address an unresolved question in the field, defining key determinants of a) liver cancer development in specific cohorts of patients with metabolic-associated fatty liver disease (MAFLD), which is the leading cause of liver cancer in adults; and b) progression of hepatoblastoma, the primary form of liver cancer in children.
WP3Molecular tumour-host interactions
It will use cutting-edge molecular technologies, such as single-cell sequencing and spatial transcriptomics, to provide insights regarding tumour-host interactions in liver cancer
WP4Intratumoral microbiome
In WP4, we will dissect liver tumours from a completely unique angle, namely exploring the role of the intratumoral microbiome and its implication in tumour-host interactions.
WP5Biomarkers of response to treatment
It will be devoted at identifying biomarkers of response/resistance to immune-based therapies in hepatocellular carcinoma, and of resistance to chemotherapy in paediatric hepatoblastoma patients, considering molecular, immune and microbiome factors.
WP6Artificial-intelligence-based biomarkers of response to treatment
We will specifically develop artificial-intelligence-based tools using high-resolution histological images to further explore prediction of response in hepatocellular carcinoma and hepatoblastoma
WP7New therapies
Knowledge derived from WP2 to WP6 will fuel WP7, devoted to identifying novel therapeutic strategies aimed at overcoming resistance to the current standard-of-care therapies in childhood and adult liver cancer patients
WP8Data integration to UNCAN.eu
The UNCAN.eu initiative aims to achieve the next breakthrough needed to advance the understanding of cancer mechanisms in order to improve cancer prevention, early diagnosis and treatment, providing a basis for saving millions of European citizens’ lives
WP9Project management and coordination
It will be dedicated to the THRIVE project management and coordination
WP10Communication, dissemination and exploitation
It will deal with communication & dissemination of all THRIVE information generated, exploitation and interaction with EU funded activities.
WP11Promoting social impact
It will ensure the social impact and viability of THRIVE beyond the grant period; and promote networking, exchange of knowledge, establishment of best practices and interaction with patients and policymakers.